Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Vir Biotechnology typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action reveals extreme volatility around Vir's earnings releases, with an average absolute Day +1 move of 12.50% and an average Day +1 range of 15.70%. The most dramatic reaction came in February 2026, when the stock surged 27.73% the day after earnings, followed by an 18.03% intraday range. Conversely, the May 2026 report triggered a 9.91% decline on Day +1.

The Day 0 moves are relatively muted at 1.44% on average, consistent with after-hours reporting where initial reactions occur in extended trading rather than the regular session. However, the Day +1 follow-through has been substantial and bidirectional, with five of the past eight reports producing double-digit percentage moves. This pattern suggests investors should brace for significant price swings regardless of whether the company beats or misses estimates, as the market appears to react more to forward guidance and pipeline updates than to the quarterly numbers themselves.

Part 2.2: Options Market Expected Move

The options market is pricing a 6.44% expected move through the November 20 expiration, significantly below the 12.50% average historical Day +1 move. This suggests options traders may be underestimating potential volatility, presenting either an opportunity for options buyers or indicating that market participants expect a less dramatic reaction than historical patterns would suggest.

Part 3: What Analysts Are Saying

Analysts maintain a "Strong Buy" consensus on Vir Biotechnology with an average price target of $21.00, implying 87% upside from the current $11.22 price. The rating breakdown shows overwhelming bullish sentiment with 9 Strong Buy ratings and 1 Moderate Buy, though this is tempered by 1 Strong Sell rating. The high target estimate of $30.00 suggests some analysts see potential for the stock to nearly triple, while even the low target of $15.00 implies 34% upside.

However, sentiment has deteriorated over the past month, with the average recommendation slipping from 4.73 to 4.55. One month ago, the consensus included 1 Hold rating and no Strong Sells; today, that Hold has been replaced by a Strong Sell, indicating at least one analyst has turned decidedly negative. The total analyst count remains at 11, suggesting stable coverage despite the sentiment shift.

The deterioration appears driven by concerns about execution risk and valuation following the stock's 88% surge over the past year. While the $21.00 consensus target still implies substantial upside, the recent downgrade to Strong Sell by one firm and Zacks Research's shift to a "strong sell" rating highlight growing skepticism about whether the clinical-stage company can justify its $1.90 billion market cap given projected losses of -$1.84 per share for fiscal 2026 and -$2.61 for fiscal 2027. Despite these concerns, the overwhelming majority of analysts remain bullish, with recent price target increases from HC Wainwright (to $22) and Morgan Stanley ($25) reflecting confidence in the pipeline's long-term potential.

Part 4: Technical Picture

Vir Biotechnology enters earnings with a moderately bullish technical setup, though momentum has softened recently. The Barchart Technical Opinion currently shows an 80% Buy signal, down from 88% Buy one week ago and 100% Buy one month ago, indicating some deterioration in technical strength as the stock consolidates near its 52-week high of $12.19.

Timeframe Analysis:

• Short-term (50% Buy): Neutral-to-bullish signal suggests near-term momentum has stalled after the recent rally, with the stock digesting gains
• Medium-term (100% Buy): Strong buy signal indicates the intermediate trend remains firmly positive, supporting the stock's position above all major moving averages
• Long-term (100% Buy): Strong buy signal reflects the powerful 88% advance over the past 52 weeks, confirming the broader uptrend remains intact

Trend Characteristics: The combination of Average strength and Average direction suggests the stock is in a stable uptrend without extreme momentum characteristics, providing a balanced technical environment heading into earnings rather than an overheated or oversold condition.

The stock is trading at $11.22, positioned above its 10-day ($11.14), 20-day ($10.97), 50-day ($10.99), 100-day ($10.20), and 200-day ($9.57) moving averages, though it sits below the 5-day moving average of $11.44. This alignment above longer-term averages confirms the uptrend, while the slight pullback from the 5-day MA suggests recent consolidation.

Key technical levels to watch include the 50-day moving average at $10.99, which has provided support during recent pullbacks, and the 52-week high of $12.19 as immediate resistance. The RSI reading of 52.73 indicates neutral momentum—neither overbought nor oversold—giving the stock room to move in either direction post-earnings. With the stock trading just 8.6% below its 52-week high but above all major moving averages, the technical setup is cautiously supportive heading into the release. However, the recent weakening in the short-term signal and the stock's proximity to resistance suggest limited cushion for disappointment, while a strong beat could quickly propel VIR to new 52-week highs. The 1.59 beta indicates the stock tends to amplify market moves, adding to potential volatility around the earnings event.